Publications by authors named "K R Tuttle"
Objective: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes and high cardiovascular risk in the SURPASS-4 trial. To examine the generalizability of these findings, we assessed change from baseline in UACR for tirzepatide (5, 10, and 15 mg) compared with active and placebo treatment in a broad population from the SURPASS-1-5 trials.
Research Design And Methods: This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Of the nearly 600,000 people in the U.S. who receive dialysis for chronic kidney failure, >60% have diabetes.
View Article and Find Full Text PDFBackground And Aim: Kidney transplant recipients frequently experience a wide range of metabolic complications, including weight changes, which significantly impact patient outcomes and graft function, yet the relationship between weight gain and transplant outcomes remains poorly understood. This systematic review and meta-analysis aimed to synthesise existing evidence on the influence of weight gain on patient and graft outcomes following kidney transplantation to enhance clinical practice and optimise post-transplant care strategies.
Materials And Methods: A literature search was conducted across databases such as PubMed and Scopus for peer-reviewed studies published up to 8 August 2024.
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials.
View Article and Find Full Text PDFArticle Synopsis
- * The KDOQI Work Group generally agrees with KDIGO's suggestions for CKD evaluation, management options, and the use of new medications such as SGLT2 inhibitors for various CKD types, particularly in patients with diabetes.
- * The guidelines stress team-based care as essential in addressing CKD challenges, and the work group has identified barriers and opportunities for implementing these new recommendations while continuing research on early CKD detection and treatment.